IPN Stock Overview
Operates as a biopharmaceutical company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IPN from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €109.60 |
| 52 Week High | €123.70 |
| 52 Week Low | €100.50 |
| Beta | 0.62 |
| 1 Month Change | -0.72% |
| 3 Month Change | -1.70% |
| 1 Year Change | 1.67% |
| 3 Year Change | 35.61% |
| 5 Year Change | n/a |
| Change since IPO | 28.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPN | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 2.0% | -4.1% | 0.9% |
| 1Y | 1.7% | -1.3% | -1.2% |
Return vs Industry: IPN exceeded the Austrian Pharmaceuticals industry which returned -1.2% over the past year.
Return vs Market: IPN exceeded the Austrian Market which returned -1.2% over the past year.
Price Volatility
| IPN volatility | |
|---|---|
| IPN Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in AT Market | 6.2% |
| 10% least volatile stocks in AT Market | 2.2% |
Stable Share Price: IPN has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: IPN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
| IPN fundamental statistics | |
|---|---|
| Market cap | €8.93b |
| Earnings (TTM) | €663.90m |
| Revenue (TTM) | €3.44b |
13.4x
P/E Ratio2.6x
P/S RatioIs IPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPN income statement (TTM) | |
|---|---|
| Revenue | €3.44b |
| Cost of Revenue | €618.00m |
| Gross Profit | €2.82b |
| Other Expenses | €2.15b |
| Earnings | €663.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 8.08 |
| Gross Margin | 82.01% |
| Net Profit Margin | 19.33% |
| Debt/Equity Ratio | 9.6% |
How did IPN perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield15%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:36 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ipsen S.A. is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Charles Pitman-King | Barclays |
| Hae Won Na | Berenberg |